Valuable experience in the biotherapeutics sector
2020 BioCanRx Summer Studentships (4 Months)
Start date: May 2020
End date: August 2020
BioCanRx Summer Studentships provide funding for undergraduate and college students to gain work experience in the Canadian cancer biotherapeutics research sector. The competitive application process ensures that, at the centre of these studentships, are innovative research projects and mentors dedicated to training the next generation of highly qualified personnel.
This funding opportunity is open to BioCanRx network investigators and other Candian-based investigators researching cancer immunotherapy.
Note – at the time of the application deadline, students must have found an investigator to work with. Please refer to the Summer Student Program Details document for more information.
Deadline: Feb 28, 2020
Mitacs Accelerate Internships
Mitacs’ Accelerate internship program enables graduate students or post-doctoral fellows to bridge the gap between academia, industry and non-profit organizations. As interns under the Mitacs-Accelerate program, participating BioCanRx HQP would offer their expertise and a fresh perspective to collaborative research projects. BioCanRx would like to foster innovative research collaborations within the cancer biotherapeutics sector across universities, industry, and non-profits. Any eligible projects that result will undoubtedly be interdisciplinary and offer unique opportunities for the participating trainees so we encourage interested PIs, graduate students, or post-doctoral fellows to reach out for more information. Applications are submitted to and evaluated by Mitacs.
Applications are submitted to and evaluated by Mitacs.
- Immune cell tracking to tumor microenvironment and lymphoid
- Dalhousie University and Immunovaccine Inc.
- Extracellular biomarker discovery to develop a specific therapeutic treatment in cancer
- University of British Columbia and BioMark Technologies Inc.
- Characterization of a novel humanized monoclonal antibody specific to KAL 006: Impact on lymphatic metastasis in cancer
- University of Toronto and Kalgene Pharmaceuticals Inc.